UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas

Journal of clinical oncology, 2001-09, Vol.19 (17), p.3766-3770

2001

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Follow-Up of a Prospective Study of Combined Modality Therapy for Stage I–II Indolent Non-Hodgkin’s Lymphoma

Journal of clinical oncology, 2003-06, Vol.21 (11), p.2115-2122

2003

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm

Nature genetics, 1997-05, Vol.16 (1), p.74-78

1997

Link zum Volltext

Verfügbarkeit prüfen

Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha

Blood, 2005-06, Vol.105 (12), p.4573-4575

2005

Link zum Volltext

Verfügbarkeit prüfen

NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, y, 18, and 21

Cancer research (Chicago, Ill.), 2003, Vol.63 (1), p.44-51

2003

Link zum Volltext

Verfügbarkeit prüfen

Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma

Blood, 2002-12, Vol.100 (13), p.4351-4357

2002

Link zum Volltext

Verfügbarkeit prüfen

European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte‐predominant Hodgkin disease

Cancer, 2002-03, Vol.94 (6), p.1731-1738

2002

Link zum Volltext

Verfügbarkeit prüfen

An elevated serum beta‐2‐microglobulin level is an adverse prognostic factor for overall survival in patients with early‐stage Hodgkin disease

Cancer, 2002-12, Vol.95 (12), p.2534-2538

2002

Link zum Volltext

Verfügbarkeit prüfen

Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes

Oncology reports, 2003-09, Vol.10 (5), p.1513

2003

Link zum Volltext

Verfügbarkeit prüfen

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue

Cancer chemotherapy and pharmacology, 2002-05, Vol.49, p.S13-S20

HAGEMEISTER, Fredrick B

2002

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination

Investigational new drugs, 1999-05, Vol.17 (2), p.187-192

1999

Link zum Volltext

Verfügbarkeit prüfen

Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma

Seminars in oncology, 2000-12, Vol.27 (6), p.37-41

2000

Link zum Volltext

Verfügbarkeit prüfen

Induction of chromosome breaks and sister chromatid exchanges in patients with Hodgkin's disease by two combination chemotherapy regimens of different leukemogenic potential

Cancer research (Chicago, Ill.), 1990-02, Vol.50 (3), p.558-562

1990

Link zum Volltext

Verfügbarkeit prüfen

Effective Salvage Therapy for Lymphoma With Cisplatin in Combination With High-Dose Ara-C and Dexamethasone (DHAP)

Blood, 1988-01, Vol.71 (1), p.117-122

1988

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma

Journal of clinical oncology, 1992-05, Vol.10 (5), p.790-794

1992

Link zum Volltext

Verfügbarkeit prüfen

Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease

Journal of clinical oncology, 1997-12, Vol.15 (12), p.3488-3495

1997

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma

Journal of clinical oncology, 1994-03, Vol.12 (3), p.575-579

1994

Link zum Volltext

Verfügbarkeit prüfen

No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule

Journal of clinical oncology, 1996-02, Vol.14 (2), p.543-548

1996

Link zum Volltext

Verfügbarkeit prüfen

Intermediate‐grade lymphomas treated with cyclophosphamide‐doxorubicin‐vincristine‐prednisone‐bleomycin alternated with cyclophosphamide‐methotrexate‐etoposide‐dexamethasone. Application of prognostic models to data analysis

Cancer, 1994-05, Vol.73 (9), p.2408-2416

1994

Link zum Volltext

Verfügbarkeit prüfen

Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma

The American journal of medicine, 1989-08, Vol.87 (2), p.167-172

1989

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy With Dexamethasone, High-Dose Cytarabine, and Cisplatin for Parenchymal Brain Lymphoma

JNCI : Journal of the National Cancer Institute, 1988-11, Vol.80 (17), p.1408-1412

1988

Link zum Volltext

Verfügbarkeit prüfen

Treatment of lower torso stages I and Ii Hodgkin's disease with radiation with or without adjuvant mechlorethamine, vincristine, procarbazine, and prednisone

Cancer, 1990-07, Vol.66 (1), p.69-74

1990

Link zum Volltext

Verfügbarkeit prüfen

Prognostic factors for stage IV Hodgkin's disease treated with MOPP, with or without bleomycin

Cancer, 1985-02, Vol.55 (4), p.691-697

1985

Link zum Volltext

Verfügbarkeit prüfen

Combined modality therapy in stage III and stage IIIE diffuse large cell lymphomas

Cancer, 1984-04, Vol.53 (7), p.1478-1483

1984

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 27

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBritish Journal Of Haematology

ThemaPharmacology. Drug Treatments

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Biological And Medical Sciences
(27)
Medical Sciences
(27)
Humans
(26)
Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Antineoplastic Agents
(22)
Middle Aged
(21)
Adult
(20)
Oncology
(20)
Male
(19)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(18)
Female
(17)
Aged
(16)
Chemotherapy
(14)
Combined Modality Therapy
(11)
Lymphoma, Non-Hodgkin - Drug Therapy
(10)
Combined Treatments
(9)
Hodgkin Disease - Drug Therapy
(9)
Prognosis
(9)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas

Long-Term Follow-Up of a Prospective Study of Combined Modality Therapy for Stage I–II Indolent Non-Hodgkin’s Lymphoma

Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia

Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm

Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha

NOVP chemotherapy for Hodgkin's disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, y, 18, and 21

Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma

European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte‐predominant Hodgkin disease

An elevated serum beta‐2‐microglobulin level is an adverse prognostic factor for overall survival in patients with early‐stage Hodgkin disease

Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue

Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination

Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma

Induction of chromosome breaks and sister chromatid exchanges in patients with Hodgkin's disease by two combination chemotherapy regimens of different leukemogenic potential

Effective Salvage Therapy for Lymphoma With Cisplatin in Combination With High-Dose Ara-C and Dexamethasone (DHAP)

Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma

Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease

Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma

No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule

Intermediate‐grade lymphomas treated with cyclophosphamide‐doxorubicin‐vincristine‐prednisone‐bleomycin alternated with cyclophosphamide‐methotrexate‐etoposide‐dexamethasone. Application of prognostic models to data analysis

Refractoriness to chemotherapy and poor survival related to abnormalities of chromosomes 17 and 7 in lymphoma

Chemotherapy With Dexamethasone, High-Dose Cytarabine, and Cisplatin for Parenchymal Brain Lymphoma

Treatment of lower torso stages I and Ii Hodgkin's disease with radiation with or without adjuvant mechlorethamine, vincristine, procarbazine, and prednisone

Prognostic factors for stage IV Hodgkin's disease treated with MOPP, with or without bleomycin

Combined modality therapy in stage III and stage IIIE diffuse large cell lymphomas

Aktive Filter

Suchergebnisse filtern